- Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 -
SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023.
To date, 20 sites have been initiated and are enrolling for the potentially pivotal Phase 2 clinical study, FIRCE-1. The Phase 2 trial (NCT05972720) is an open-label, multicenter Phase 2 clinical study evaluating the efficacy and safety of firicabtagene autoleucel (firi-cel) (CRG-022) in patients with relapse or refractory (R/R) large B-cell lymphoma (LBCL) whose disease has progressed after CD19-directed CAR T-cell therapy, an area of high unmet need. Interim results are anticipated in the first half of 2025.
"2023 was a transformative year for CARGO as we built our leadership team and attracted top talent, initiated FIRCE-1, a potentially pivotal Phase 2 clinical study of CRG-022, which we are now calling firi-cel, and executed a successful private financing and IPO, fortifying a strong financial position," said Gina Chapman, President and Chief Executive Officer of CARGO. "Our team has the expertise and experience to engineer, develop and deliver a next generation of potentially curative therapies to patients with high unmet need in cancer with a commercial-ready manufacturing process."
In December 2023, CARGO summarized results regarding an ongoing Phase 1 clinical study (being conducted by Stanford University (Stanford)) (NCT04088890) in patients with LBCL that were R/R to CD19 CAR T-cell therapy. At Dose Level 1 (n=29), the dose CARGO is using for its Phase 2 clinical trial, firi-cel (CRG-022) was well-tolerated and complete response (CR) rate was 52%, with 73% of patients who achieved a CR maintaining CR for at least 12 months, as of the November 4, 2023 cut-off date.
Other Corporate Highlights
- Completed an initial public offering (IPO) raising approximately $291.0 million in net proceeds.
- Added to the Russell 2000® Index on March 15, 2024.
Fourth Quarter and Year-End Financial Results
- CARGO had $405.7 million in cash and cash equivalents as of December 31, 2023, which it expects will fund operations through 2025.
- Research and development (R&D) expenses were $27.1 million for the fourth quarter of 2023, which includes $0.7 million of non-cash stock-based compensation expense. For 2023, R&D expenses were $75.8 million, which includes $1.3 million of non-cash stock-based compensation expense.
- General and administrative (G&A) expenses were $7.9 million for the fourth quarter of 2023, which includes $1.0 million of non-cash stock-based compensation expense. For 2023, G&A expenses were $20.9 million, which includes $2.0 million of non-cash stock-based compensation expense.
- Net loss for the fourth quarter of 2023 was $32.1 million, or $1.49 per share, including non-cash stock-based compensation and depreciation expenses of $1.7 million and $0.5 million, respectively. For 2023, net loss was $98.1 million, or $16.53 per share, including non-cash stock-based compensation and depreciation expenses of $3.3 million and $1.5 million, respectively.
About CARGO Therapeutics
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. CARGO's programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating its lead program, firicabtagene autoleucel (firi-cel) (CRG-022), an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical study in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO also plans to evaluate firi-cel (CRG-022) in patients at earlier stages of disease, including LBCL and other hematologic malignancies. Beyond its lead program, CARGO is leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic "cargo" designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. CARGO's founders are pioneers and world-class experts in CAR T-cell therapy, and its team has significant experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at https://cargo-tx.com/.
Follow us on LinkedIn: CARGO Therapeutics
Follow us on X (Twitter): @CARGOTx
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: advancement of CARGO's clinical programs; the potential benefits from treatment with CD19 CAR T-cell therapies; timing of data reports, including the release of interim data from the Company's ongoing Phase 2 clinical trial of CRG-022; the implementation of CARGO's strategic plans for its business and product candidates; and whether the Company's cash and cash equivalents will be able to fund operations through 2025. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company's product candidates; the company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company's product candidates; the company's reliance on third-party suppliers and manufacturers, including CROs; the outcomes of any future collaboration agreements; and the company's ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled "Risk Factors" contained in the company's prospectus filed with the Securities and Exchange Commission (SEC) on November 13, 2023 pursuant to Rule 424(b) under the Securities Act and the company's other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
| CARGO Therapeutics, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) | |||||||||||||||
| Three months ended December 31, | Year ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 27,067 | $ | 9,231 | $ | 75,791 | $ | 29,373 | |||||||
| General and administrative | 7,889 | 1,774 | 20,919 | 5,398 | |||||||||||
| Total operating expenses | 34,956 | 11,005 | 96,710 | 34,771 | |||||||||||
| Loss from operations | (34,956 | ) | (11,005 | ) | (96,710 | ) | (34,771 | ) | |||||||
| Other income (expense), net | 2,879 | (2,744 | ) | (1,437 | ) | (6,180 | ) | ||||||||
| Net loss and comprehensive loss | $ | (32,077 | ) | $ | (13,749 | ) | $ | (98,147 | ) | $ | (40,951 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (1.49 | ) | $ | (25.62 | ) | $ | (16.53 | ) | $ | (104.40 | ) | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 21,563,893 | 536,579 | 5,938,782 | 392,268 | |||||||||||
| CARGO Therapeutics, Inc. Condensed Balance Sheet Data (in thousands) | |||||||
| December 31, | |||||||
| 2023 | 2022 | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 405,732 | $ | 1,872 | |||
| Other assets | 47,304 | 8,371 | |||||
| Total assets | $ | 453,036 | $ | 10,243 | |||
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | |||||||
| Liabilities | $ | 47,650 | $ | 45,479 | |||
| Stockholders' equity (deficit) | 405,386 | (35,236 | ) | ||||
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $ | 453,036 | $ | 10,243 | |||
Find more information at cargo-tx.com
Follow us on LinkedIn: CARGO Therapeutics
Follow us on X (Twitter): @CARGOTx
Media Contact:
Maura Gavaghan
maura@redhousecomms.com
Investor Contact:
Laurence Watts
laurence@gilmartinir.com
